



Design and Synthesis of Small Organic Molecules having Potential Biological Activity

Thesis Presented by

Eman Moussa Mohammed El-labbad

BSc. in Pharmaceutical Sciences (May 2005)

MSc. in Pharmaceutical Sciences (Pharmaceutical Chemistry) (March 2011)

Assistant Lecturer of Pharmaceutical Chemistry

Faculty of Pharmacy

Ain Shams University

Submitted for the partial fulfilment of the

Doctorate of Philosophy Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

Under the supervision of

Khaled Abouzid Mohamed Abouzid

*Professor and Chairman of Pharmaceutical Chemistry
Department*

Faculty of Pharmacy

Ain Shams University

Binghe Wang

*Regents Professor and Associate Dean for Natural and
Computational Sciences*

Chemistry Department

Georgia State University

Rabah A.T. Serya

Assistant Professor of Pharmaceutical Chemistry

Faculty of Pharmacy

Ain Shams University

Deena S. Lasheen

Lecturer of Pharmaceutical Chemistry

Faculty of Pharmacy

Ain Shams University

Faculty of Pharmacy

Ain Shams University

2017

Acknowledgements

It's a pleasure to express my sincere appreciation to **Professor Khaled Abouزيد Mohamed Abouزيد**, Professor and Chairman of Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, for his scientific supervision, fruitful opinion, valuable advices and continuous encouragement. I am indebted to him for his guidance and endless support.

I would like to express my sincere gratitude and thankfulness to **Professor Binghe Wang**, Regents Professor and Associate Dean for Natural and Computational Sciences, Georgia State University, for giving me the opportunity to join his laboratory for one years. I appreciate his innovative ideas, scientific supervision, wise mentoring, guidance and encouragement.

I owe my truthful gratitude to **Dr. Rabah A.T. Taha**, Assistant Professor of Pharmaceutical Chemistry and **Dr. Deena S. Lasheen** Lecturer of Pharmaceutical Chemistry, for their continuous encouragement and support. I am heartily grateful to their real interest, trust, caring, and eminent guidance.


I am sincerely thankful for **Dr. Xingyue Ji**, Postdoctoral Fellow and Research Scientist at Chemistry department, Georgia State University, for his wise mentoring, tremendous support. I am heartily grateful to this indispensable opinion, real interest, trust, eminent guidance and untiring help throughout the whole work.

I acknowledge with thankfulness all my colleagues in Pharmaceutical Chemistry Department and Wang's lab members, for their friendly cooperation, support and their generous and valuable aid.

Finally, I am profoundly indebted to my family for their unconditional love and aid, endless patience, understanding, encouragement and full support all throughout the whole long way.

The work presented in this thesis was published in;

Click and Release: SO₂ Prodrugs with Tunable Release Rates


Xingyue Ji,^{†,§} Eman M. El-labbad,^{‡,§} Kaili Ji,[†] Deena S. Lasheen,[‡] Rabah A. T. Serya,[‡] Khaled A. Abouzid,[‡] and Binghe Wang^{*,†} 

[†]Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia 30303 United States

[‡]Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, Egypt

Supporting Information

ABSTRACT: Employing an intramolecular cycloaddition reaction, we have developed a series of SO₂ prodrugs with tunable release rates with half-lives ranging from minutes to days.



Org. Lett., **2017**, *19* (4), pp 818–821

DOI: 10.1021/acs.orglett.6b03805

Publication Date (Web): January 30, 2017

Copyright © 2017 American Chemical Society

Content

List of Figures.....	<i>I</i>
List of Tables.....	<i>V</i>
Abbreviations.....	<i>VI</i>
Abstract.....	<i>IX</i>
1.Introduction.....	<i>1</i>
1.1.Gasotransmitters Definition, Criteria and Classification	<i>1</i>
1.2. Biological and therapeutic role of gasotransmitters.....	<i>3</i>
1.2.1. Nitric Oxide (NO).....	<i>3</i>
1.2.2. Carbon Monoxide (CO).....	<i>6</i>
1.2.3. Hydrogen Sulfide (H ₂ S).....	<i>8</i>
1.2.4. Sulfur Dioxide (SO ₂).....	<i>10</i>
1.2.5. Shared signaling pathway among gasotransmitters (NO, CO, H ₂ S and SO ₂)	<i>14</i>
1.2.6. Gasotransmitters and cancer.....	<i>15</i>
1.3.Exogenous gasotransmitters drug delivery systems.....	<i>18</i>
1.3.1. Inhalation Form.....	<i>18</i>
1.3.2. Small Molecules.....	<i>19</i>
1.3.2.1. Metal based releasing molecules.....	<i>19</i>
1.3.2.1.a. NO Metal based releasing molecules.....	<i>19</i>
1.3.2.1.b CO Metal based releasing molecules.....	<i>20</i>
1.3.2.2. Enzyme triggered releasing molecules.....	<i>21</i>
1.3.2.2.a. Enzyme triggered NO-releasing molecules.....	<i>22</i>
1.3.2.2.b. Enzyme triggered CO-Releasing molecules.....	<i>22</i>
1.3.2.2.c. Enzyme Triggered H ₂ S- Releasing Molecules.....	<i>24</i>
1.3.2.3. Photosensitive organic releasing molecules.....	<i>25</i>
1.3.2.3.a Photo-sensitive organic CO-Releasing Molecules.....	<i>25</i>

1.3.2.3.b Photo-sensitive organic SO ₂ -Releasing Molecules.....	26
1.3.2.3.c Photo-sensitive organic H ₂ S-Releasing Molecules.....	27
1.3.2.4.Thiol Activated Releasing Molecules.....	27
1.3.2.4.a. Thiol activated NO Releasing Molecules.....	28
1.3.2.4.b. Thiol activated H ₂ S Releasing Molecules.....	29
1.3.2.4.c Thiol activated SO ₂ Releasing Molecules.....	30
1.3.2.5. Organic compounds release gasotransmitters under physiological conditions.....	31
1.3.3.Materials and polymers.....	36
2. Rationale and Design.....	38
3. Results and Discussion.....	44
3.1. Chemistry.....	44
3.1.1.Scheme (1).....	44
3.1.2.Scheme (2).....	51
3.1.3.Scheme (3).....	53
3.1.4.Scheme (4).....	62
3.2. Amide rotamers and ¹ H NMR temperature dependent study.....	65
3.3.Verification of SO ₂ release.....	67
3.4.Kinetic Study of SO ₂ Release.....	70
3.5. Conformation analysis study for prodrugs (XVa) and (XVc).....	75
3.6.Biology.....	79
4. Conclusion and Future Perspective.....	83
5. Experimental.....	85
5.1. Chemistry.....	85
5.1.1. Materials and methods.....	85
5.1.2. Synthssis.....	85

5.1.2.1. Scheme (1).....	85
5.1.2.2. Scheme (2).....	89
5.1.2.3. Scheme (3).....	92
5.1.2.4. Scheme (4).....	96
5.2.Verification of SO ₂ release.....	100
5.3.Kinetic study of SO ₂ release.....	104
5.4.Biology.....	110
6. Supplementary Data.....	111
7. References.....	137

List of Figures

Figure (1): Publication trends on gasotransmitter research.....	2
Figure (2): Generation of Nitric oxide from L-arginine by nitric oxide synthase.....	3
Figure (3): Nitric oxide generation by eNOS. Several stimuli induce eNOS activation and NO production in endothelia cells.....	4
Figure (4): (A) Nitric oxide generation by nNOS. (B). Nitric oxide generation by iNOS showing the activation of iNOS promoter requires interferon regulatory factor 1 and nuclear factor K-light-chain-enhancer of activated B cells.	5
Figure (5): Endogenous production of CO.....	7
Figure (6): The biosynthesis and degradation of hydrogen sulfide (H ₂ S) in mammalian cells	8
Figure (7): Endogenous H ₂ S synthesis.....	9
Figure (8): Known molecular targets for hydrogen sulfide (H ₂ S)	10
Figure (9): The production and metabolism of SO ₂ in mammalian cells.	11
Figure (10): Signaling pathway involved in the effect of SO ₂	12
Figure (11): A schematic diagram of the inhibition of proliferation by SO ₂	12
Figure (12): Signaling pathways of NO, CO, and H ₂ S and SO ₂ in vascular smooth muscle cells.....	14
Figure (13): Implications of the bell-shaped pharmacological profile of gasotransmitters for the therapy of cancer.	15
Figure (14): Pro-tumor effects of low levels of endogenously produced NO, carbon monoxide (CO) and hydrogen sulfide (H ₂ S)	17
Figure (15): Exogenous gasotransmitters drug delivery methods.	18
Figure (16): The mechanism of release of NO from sodium nitroprusside.	20
Figure (17): The general concept of acyloxycyclohexadiene iron tricarbonyl enzyme trigger carbon monoxide releasing molecules.	22
Figure (18): Design strategy of protease-activated ET-CO-RMs.	23
Figure (19): Mechanism of release of H ₂ S from esterase sensitive prodrugs (12,13). A) Design strategy of esterase sensitive-H ₂ S donor. B) mechanism of H ₂ S release from	

prodrug (12). C) Mechanism of release of naproxen and H ₂ S from the hybrid prodrug (13).	24
Figure (20) . The photoreaction of 3-hydroxyflavone analogues (14a-d).	25
Figure (21) : The design strategy and SO ₂ release mechanism of benzosultines (15a-c) and benzosulfones (17) SO ₂ donors.	26
Figure (22) : The design strategy and release mechanism of photosensitive H ₂ S donors. A) The design strategy of photocaged H ₂ S-based photosensitive H ₂ S prodrugs. B) The design strategy of photocaged gem-dithiol photosensitive H ₂ S donors.	27
Figure (23) : The mechanism of release of NO glutathione activated NO -donor (21).	28
Figure (24) : The design strategy and H ₂ S release mechanism from thiol activated H ₂ S donor. (A) The Design of (acylthiol) benzamide thiol activated H ₂ S donor. (B) The design strategy of perthiol -thiol activated H ₂ S donor. (C) The proposed mechanism of H ₂ S release from prodrug (acylthiol) benzamide thiol activated H ₂ S donor.	29
Figure (25) . Proposed mechanism for thiol-mediated SO ₂ generation from 2,4-dinitrophenylsulfonamides (24).	30
Figure (26) . Mechanism of release of SO ₂ from benzosthiazole sulfonate prodrug (25).	31
Figure (27) : The design strategy of “click and release” CO or SO ₂ bimolecular prodrugs.	32
Figure (28) : The click reaction between TPCPDs (26) and BCNs (27).	33
Figure (29) : The bimolecular SO ₂ drug system based on click reaction between BCN and Thiophene-S-dioxide.	34
Figure (30) : The mechanism of CO release after intramolecular click reaction of CO-prodrugs 32a-g , fluorophore formed in CP-34a-g is colored in blue.....	35
Figure (31) : Design strategy of a unimolecular SO ₂ prodrug showing click and release strategy.....	39
Figure (32) : Mechanism of SO ₂ release from the designed thiophene-S-dioxide prodrugs.....	40
Figure (33) : Proposed mechanism of click reaction between thiophene-S-dioxide moiety and alkyne side chain of compound XVa via intramolecular inverse electron demanded Diels-Alders cycloaddition reaction based on frontier orbital description.	41
Figure (34) : Mechanism of Hinsberg thiophene synthesis. A) Proposed mechanism via clasein -type condensation. B) Mechanism proposed by Hans Wynberg and H. J.	

Kooreman via Stobbe-type condensation C) Thiophene condensation using O ¹⁸ - enriched benzil.	45
Figure (35): Hinsberg thiophene synthesis using <i>De novo</i> polymer supported system...	46
Figure (36): Mechanism of carbodiimide / DMAP- mediated ester/amide coupling. ...	48
Figure (37): Different strategies used in amide bond formation.....	54
Figure (38): Alcohols commonly used in amide bond formation via active ester procedure.....	56
Figure (39) The NHS ester aminolysis mechanism proposed by Cline <i>et al.</i>	57
Figure (40): Mechanism of amide bond coupling reaction using acyl chlorides. A) Mechanism of acyl chloride formation using thionyl chloride or oxalyl chloride. B) The catalytic role of DMF.....	59
Figure (41): Mechanism of acid chloride formation by cyanuric chloride.	59
Figure (42): Catalytic role of Pyridine and DMAP in coupling reaction of acid chloride and amine.....	60
Figure (43): Oxidation of XIIa-d	61
Figure (44): Amide rotamer and ¹ H NMR temperature dependent study. (A) Resonance form of amide showing C-N bond partial double bond character and C-O partial single bond character. (B) Potential rotational isomers of prodrug (XVIa). (C) ¹ H NMR spectra of prodrug (XVIa) at 25 °C. (D) Temperature dependent ¹ H NMR study of prodrug (XVIa) in CDCl ₃ . Three pairs of protons were present at 25 °C, yet they begin to coalesce as temperature increased to 60 °C indicating that these rotamers are thermodynamic equilibrium.	66
Figure (45): Cyclized product (CP-XVa-c) and (CP-XVIa,b) formation after incubation of solution of prodrugs (XVa,b) and (XVIa-c) in DMSO/PBS (1:1) at 37 °C for 1-24 hours.....	67
Figure (46): (A) Mechanism of SO ₂ detection using DTNB. B) UV absorption at 412 nm of DTNB test after 30 min incubation at room temperature or 37 °C.....	69
Figure (47): Absorbance spectra of the prodrugs XVa-c and XVIa,b and their corresponding cyclized product CP-XVa-c and CP-XVIa,b	70
Figure (48): ¹ H NMR experiment demonstrates the sluggish SO ₂ release and slow cyclization rate of VIb incubated in DMSO- <i>d</i> ₆ /D ₂ O at 37 °C.....	72

Figure (49): ^1H NMR experiment to investigate the cyclization of XVb incubated in CDCl_3 at 37°C	73
Figure (50): Dipole repulsion of ester favours transoid geometry.....	74
Figure (51): Proposed 2D conformation for(XVa) showing HB between amidic proton and the oxygen of S-dioxide disfavoring the intended cycloaddition.	74
Figure (52) The SO_2 release kinetics for XVc in CH_3CN	75
Figure (53): 2D diagram of the suggested Cis-trans geometries of designed prodrugs and their effect on the intended Diels-Alders cycloaddition reaction. (A). 2D diagram of designed prodrug showing monitored torsion angle θ . (B) The effect of cis and trans geometry on Diels Alders reactions described by frontier orbital theory.	76
Figure (54) XVa and XVc conformation analysis. (A). Energy diagram of XVa showing energy difference between the cis and trans conformations. (B) Energy diagram of XVc showing the energy difference between the cis and trans conformations.	78
Figure (55): Theory of supercoiled plasmid cleavage assay.	79
Figure (56): The mechanistic scheme proposed for metal catalysed sulphite autoxidation.	80
Figure (57): Cascade reaction of radical cation with guanine leading to formation of 8-hydroxyguanine.	80
Figure (58): The DNA cleavage assay XVb (100 mM), CP-XVb (100 mM) and bisulfite (100 mM).....	81
Figure (59): A benzo[e]indolium SO_2 fluorescent probe and its sensing mechanism.	82
Figure (60): The SO_2 release from XVb in RAW264.7 cells. a) XVb (100 μM) only; b) SO_2 probe only (10 μM); c) Bisulfite (100 μM) + SO_2 probe (10 μM); d) XVb (100 μM) + SO_2 probe (10 μM)	82
Figure (61): Tethering linker modification and their effect on tuning SO_2 release rate as revealed by prodrugs VIa,b , XVa-c and XVIa,b	83

List of Tables

Table (1). The three nitric oxide synthase isoforms.....	3
Table (2) Biological system /effect modulated by nitric oxide.	6
Table (3): Signal pathways involved in the pathophysiological effects of SO ₂	13
Table (4) The changes in the expression of gasotransmitter-producing enzymes in various forms of cancer.	16
Table (5): SO ₂ release profiles of BTS (0.4mM) in various pH buffers.	32
Table (6): Advantages and disadvantages of different gasotransmitter delivery methods.....	37
Table (7): Wave lengths used for kinetic studies of SO ₂ release rate for prodrugs XVa-c and XVIa,b	70
Table (8) The average reaction rate constant K and half life t _{1/2} for prodrugs Vla,b , XVa-c and XVIa,b	71
Table (9) showing UV absorption at 412 nm of DTNB test after 30 min incubation at room temperature or 37 °C.....	104

List of Abbreviation

3-MST	3-Mercaptopyruvate sulfurtransferase
AC	Adenylyl cyclase
Akt	Protein kinase B (PKB), also known as Akt
ATP	Adenosine triphosphate
bax	Apoptosis regulator BAX, also known as bcl-2-like protein
Bcl-2	(B-cell lymphoma 2
BCN	Bicyclo-[6.1.0]nonyne
BH4	6R-5,6,7,8-Tetrahydro-L-biopterin
BK _{Ca}	Big-conductance calcium sensitive K channels
Boc	Tert-butyloxycarbonyl
BTS	Benzothiazole sulfinat
cAMP	Cyclic adenosine monophosphate
cAMP	3'-5'-cyclic adenosine monophosphate;
CAT	Cysteine aminotransferase
CBS	Cystathionine-β- synthase
CDO	Cysteine dioxygenase
cGMP	Cyclic guanosine monophosphate
CL	Cysteine lyase
CO-RM	Carbon monoxide releasing molecules
c-Raf	Rapidly accelerated fibrosarcoma (isoform c)
CSE	Cystathionine-γ- lyase
CVDs	Cardiovascular diseases
DAPI	4',6-Diamidino-2-phenylindole
DAR _{INV}	Inverse electron Demand Diel Alders reaction
DCC	N,N'-Dicyclohexylcarbodiimide
DCM	Dichloromethane
DCU	Dicyclohexylurea
DI	Deionized
DIC	N,N'-Diisopropylcarbodiimide
DIPEA	N,N-Diisopropylethylamine
DMAP	4-Dimethylaminopyridine
DMD	Dimethyl dioxirane
DMF	Dimethylformamide
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DTNB	5,5'-Dithiobis(2-nitrobenzoic acid)
EDC	N-Ethyl-N' - (3-dimethylaminopropyl)carbodiimide
EDRF	Endothelium-derived relaxing factor

eNOS	Endothelial nitric oxide synthase
EPC	Endothelial progenitor cells
Erk/MAPK	Extracellular signal-regulated kinases/mitogen-activated protein kinase
Et ₃ N	Triethylamine
ET-CO-RMs	Enzyme triggered carbon monoxide releasing molecules
Fmoc	Fluorenylmethyloxycarbonyl
GSH	Reduced glutathione
GSH- Px	Glutathione peroxidase
GSSG	Oxidized glutathione
GTP	Guanosine triphosphate
HIF1 α	Hypoxia-inducible factor 1 α
HL-60	Human promyelocytic leukemia cells
HO-1	Heme oxygenase-1
HOAt	Hydroxy-7-azabenzotriazole
HOBt	Hydroxybenzotriazole
HOMO	Highest occupied molecular orbital
HONB	Hydroxy-5-norbornene-endo-2,3-dicarboxyimide
HPLC	High performance liquid chromatography
HRMS (ESI)	High resolution mass spectrometry (electron spray ionization)
IBD	Inflammatory bowel diseases
ICAM-1	Intercellular Adhesion Molecule 1, also known as Cluster of Differentiation 54
IK _{Ca}	Intermediate-conductance calcium sensitive K channels
IL	Interleukin
iNOS	Inducible Nitric Oxide Synthase
LPS	Lipopolysaccharide
LUMO	Lowest unoccupied molecular orbital
mCPBA	m-Chloroperbenzoic acid
MeCN	Acetonitrile
MEK-1	Mitogen-activated protein kinase 1
MERK	Extracellular signal-regulated kinases
MOPS	(3-(N-morpholino)propanesulfonic acid
MPO	Myeloperoxidase
MPTP	Mitochondrial permeability transition pore
MSBT	Methyl sulfonyl benzothiazole
NADPH	Nicotinamide-adenine-dinucleotide phosphate
NBS	N-bromosuccinimide
NF-E2	Nuclear factor erythroid 2 related factor 2
NF- κ B	Nuclear factor κ B;

NHS	N-hydroxy succinimide
NMR	Nuclear magnetic resonance
nNOS	Neuronal Nitric Oxide Synthase
NOS	Nitric Oxide Synthase
Nrf-2	Nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2,
NSAID	Non-steroidal anti-inflammatory drug
PBS	Phosphate buffered saline
PDE-5	Phosphodiesterase-5
PDGF-BB	Platelet-derived growth factor (PDGF)- BETA BETA CHAIN
PFP	Pentafluorophenol
pERK,	Phosphorylated ERK
PGI ₂	Prostacyclin
PI3K	Phosphatidylinositol 3-kinase
PK	Protein kinase
PNP	p-nitrophenol
Ppm	Part per million
RM	Releasing molecules
sGC	Soluble guanyl cyclase
SH,	Thiol
SK _{Ca}	Small-conductance calcium sensitive K channels
SMC	Smooth muscle cells
SNP	Sodium nitroprusside
SO	Sulfite oxidase
SOD	Superoxide dismutase
SSH	Hydropersulfide
STAT3	Signal transducer and activator of transcription 3
t _{1/2}	Half life
TAE	Trisaminomethane, acetic acid, EDTA buffer system
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
TIMP1	Tissue inhibitor of metalloproteinases 1
TPCPD	Tetraphenylcyclopentadiene-1-one
Tris-Cl	Trisaminomethane or THAM (HOCH ₂) ₃ CNH ₂
TRVP	Transient receptor potential vanilloid
TsCl	Tosyl chloride
TSMT	Thiol S-methyltransferase.
UV-Vis	Ultraviolet -Visible
VEGF	Vascular endothelial growth factor
VSMC	Vascular smooth muscle cells

Abstract

Signaling molecules come in all sizes and chemical dispositions, ranging from relatively large proteins, lipids, and peptides through biogenic amines and amino acids, to gaseous molecules. Endogenously generated gaseous molecules involved in signaling process are called “Gasotransmitters”. Gasotransmitters are endogenously generated in mammalian cells with specific substrates and enzymes; their production is regulated to fulfill signaling messenger functions. They are involved in signal transduction and have specific cellular and molecular targets. Nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S) are powerful signaling molecules that play a variety of roles in mammalian biology. Recently, cumulative evidences present sulfur dioxide (SO₂) as another potential gasotransmitters.

SO₂ is a lipid soluble, membrane permeable gas molecule. SO₂ can be generated endogenously during the metabolism of sulfur-containing amino acids such as L-cysteine. Endogenous SO₂ was reported to exert a negative regulation on vascular smooth muscle cell proliferation by suppressing the Erk/MAPK pathway. Its sulfite and bisulfite derivatives also showed endothelium-independent vasorelaxation effect partially by the PGI (2)-AC-cAMP-PKA signal pathway. In addition to its physiological effects in the cardiovascular system, SO₂ also showed potentials as a therapeutic agent with a variety of pathophysiological effects, including anti-hypertensive, anti-atherosclerotic, anti-oxidative, and anti-mycobacterial effects, as well as protective effects against cardiac ischemia-reperfusion (I/R) injury.

Different investigations are required to explore the potentials of SO₂ as gasotransmitter. These investigations include: exploration of the difference between the toxic and therapeutic effects of SO₂, expanding the knowledge of physiological and therapeutic effects of SO₂ in different organs and systems, studying the possible interactions between SO₂ and other gasotransmitters and exploration of the therapeutic potential of new SO₂ donors and their possible clinical utilization. Since most the biological effects observed for SO₂ was obtained by using gaseous SO₂ or its sulfite and bisulfite (3:1) derivatives. Neither of these methods could provide controlled release of SO₂ to imitate the process of endogenous production of SO₂. Thus, there is a need for the development of prodrugs or SO₂ donors that can controllably release SO₂ under